CannaPharmaRx Q2 2026: Going Concern Doubt, $31M Working Capital Deficit, and Debt Defaults
CPMD has more than doubled off its 52-week low of $0.
Summary
CannaPharmaRx's Q2 2026 filing reveals a critical liquidity crisis: $555 in cash, $31.2M working capital deficit, going concern doubt, multiple debt defaults, and an unremediated material weakness.
Key Events · Earnings and Guidance · CPMD
-
Going Concern Doubt Reiterated
Cash of $555, working capital deficiency of $31,236,572, and accumulated deficit of $114,606,653. Management states substantial doubt about the company's ability to continue as a going concern.
-
Debt Defaults and Forbearance Expiry
Multiple notes payable and convertible notes are past maturity and in default. Koze forbearance on exercising rights over Alberta Ltd. ownership interest expires August 31, 2026.
-
Material Weakness Unremediated
Disclosure controls and internal control over financial reporting remain ineffective due to a material weakness from prior management turnover and inadequate documentation.
-
Derivative Liability Increase
Fair value of derivative conversion feature increased by $798,700 for the six months, driven by share price fluctuations, contributing to a net loss of $2,291,063.
Analysis · CPMD · Life Sciences
With only $555 in cash against a $31.2 million working capital deficiency and an accumulated deficit of $114.6 million, the company explicitly states substantial doubt about its ability to continue as a going concern. Multiple debt instruments are in default, and the forbearance agreement with Koze expires on August 31, 2026, after which the lender could seize the company's ownership interest in its operating subsidiary. The material weakness in internal controls remains unremediated. The derivative conversion feature liability increased by $798,700 due to share price fluctuations, a non-cash charge that further erodes equity. The company issued 30.2 million shares to settle $132,516 of debt at $0.0025 per share, adding to dilution. With a market cap of only $1.29 million, these conditions are existential.
At the time of this filing, CPMD was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $0.00 to $0.01. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.